Latham & Watkins advised Orbital Therapeutics on the deal. Orbital Therapeutics, which aims to enhance global health by unleashing the full potential of RNA medicine, announced...
Orbital Therapeutics’ Partnership With Beam Therapeutics
Universities Superannuation Scheme’s £300 Million Acquisition of the Real Estate Assets of Butlin’s
Gowling WLG advised private pension fund provider Universities Superannuation Scheme. The pension fund acquired the underlying real estate interest of the holiday resort operator’s sites at...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Twist Bioscience’s $250 Million Common Stock Offering
Orrick, Herrington & Sutcliffe advised Twist Bioscience, while Latham & Watkins represented the underwriters in the offering. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers...
Galderma’s Acquisition of Alastin Skincare
Ropes & Gray advised Galderma on the deal, while Latham & Watkins advised ALASTIN. Galderma, one of the world’s largest independent dermatology companies, executed its acquisition...
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
eFFECTOR Therapeutics’ Merger with Locust Walk Acquisition Corp.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
J.C. Flowers & Co and Bain Capital Credit’s Purchase Of An Equity Stake In The Co-operative Bank
Macfarlanes has advised J.C. Flowers & Co and Bain Capital Credit on the deal. J.C. Flowers & Co and Bain Capital Credit acquired an equity stake in The...
Reneo Pharmaceuticals’ $93.8 Million Initial Public Offering
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...